Most Read Articles
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

10 Jun 2018
Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.
10 Jun 2018
The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer treated with the FOLFIRI regimen, according to the results of a phase II trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.

Hydrochlorothiazide ups risk of nonmelanoma skin cancer

09 Dec 2017

Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.

Researchers compared the patterns of HCTZ use between 80,162 NMSC patients and 1,603,345 age- and sex-matched controls. Those with SCC of the lip were excluded.

Conditional logistic regression analysis was used to calculate for the risk of basal cell carcinoma (BCC) or SCC with the frequency of HTCZ use. Adjustments were performed for potential confounder such as other medications and comorbidities.

The rate of high HCTZ usage in BCC patients was higher than in matched controls (2.7 vs 2.1 percent; odds ratio [OR], 1.29; 95 percent CI, 1.23 to 1.35). Similarly, significantly more SCC patients were high HCTZ users than matched controls (10.0 vs 2.8 percent; OR, 3.98; 3.68 to 4.31).

HCTZ use also showed a dose-response relationship with BCC and SCC, with those at the highest categories of exposure having the highest risks (OR for BCC, 1.54; 1.38 to 1.71; p<0.001 for trend; OR for SCC, 7.38; 6.32 to 8.60; p<0.001 for trend).

Similar trends were observed when the participants were grouped according to sex, age and tumour localization. Notably, none of the other diuretics and hypertensives showed significant relationships with the risk of SCC and BCC.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

10 Jun 2018
Treatment with rituximab (RTX) is well tolerated and leads to stability or improvement in pulmonary function or severity of interstitial lung disease (ILD) on computed tomography (CT) in most patients, a recent study has shown.
10 Jun 2018
The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer treated with the FOLFIRI regimen, according to the results of a phase II trial.
Jairia Dela Cruz, 09 Jan 2017
The sulfonylurea glimepiride may pose an increased risk of hypoglycaemia in a subgroup of elderly type 2 diabetes (T2D) patients with lower β-cell function when added to a metformin regimen, according to a post-hoc analysis of data from the GENERATION* trial.